Macular Degeneration Treatment Advances
Anti-VEGF injections have transformed wet AMD treatment, but the burden of monthly injections drives trial research into longer-acting formulations, port delivery systems (continuous drug release via a tiny implant), and gene therapy that could enable the eye to produce its own anti-VEGF protein, potentially eliminating the need for injections entirely.
Glaucoma: Beyond Eye Drops
Glaucoma trials are moving beyond daily eye drops to explore sustained-release implants, minimally invasive glaucoma surgery (MIGS) devices, and neuroprotective drugs that preserve the optic nerve. UK centres including Moorfields Eye Hospital are leading many of these trials.
💊 Treatments
⚖️ Comparisons
📰 Related Articles
- Eye Clinical Trials UK 2026 Guide — Guide to ophthalmology trials for AMD, glaucoma, and inherited eye disease
- Glaucoma Clinical Trials UK — MIGS, neuroprotection, and gene therapy for glaucoma
- Macular Degeneration Clinical Trials UK — Anti-VEGF advances and gene therapy for AMD
Frequently Asked Questions
Are there alternatives to monthly eye injections for AMD?
Yes. Clinical trials are testing longer-acting anti-VEGF drugs (dosing every 3-6 months), port delivery systems, and gene therapy approaches. Ask your ophthalmologist about clinical trial opportunities for reduced injection frequency.
Can I join an eye trial if I have early-stage disease?
Many trials specifically target early-stage disease to test whether new treatments can prevent progression. Early intervention is a key research focus in both glaucoma and macular degeneration trials.
Find Your Clinical Trial
Search thousands of actively recruiting trials across the UK — free, instant, no registration.
Search Trials Now Read the Guide